CUV Stock Overview
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Clinuvel Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$12.01 |
| 52 Week High | AU$17.68 |
| 52 Week Low | AU$11.71 |
| Beta | 0.86 |
| 1 Month Change | -9.02% |
| 3 Month Change | -17.57% |
| 1 Year Change | -24.98% |
| 3 Year Change | -56.60% |
| 5 Year Change | -57.03% |
| Change since IPO | 679.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| CUV | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -0.5% | 1.9% | 0.5% |
| 1Y | -25.0% | 3.9% | 7.4% |
Return vs Industry: CUV underperformed the Australian Biotechs industry which returned 3.6% over the past year.
Return vs Market: CUV underperformed the Australian Market which returned 7.7% over the past year.
Price Volatility
| CUV volatility | |
|---|---|
| CUV Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: CUV has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CUV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Philippe Wolgen | www.clinuvel.com |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
Clinuvel Pharmaceuticals Limited Fundamentals Summary
| CUV fundamental statistics | |
|---|---|
| Market cap | AU$601.86m |
| Earnings (TTM) | AU$35.64m |
| Revenue (TTM) | AU$88.18m |
16.9x
P/E Ratio6.8x
P/S RatioIs CUV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUV income statement (TTM) | |
|---|---|
| Revenue | AU$88.18m |
| Cost of Revenue | AU$7.73m |
| Gross Profit | AU$80.45m |
| Other Expenses | AU$44.81m |
| Earnings | AU$35.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.71 |
| Gross Margin | 91.23% |
| Net Profit Margin | 40.41% |
| Debt/Equity Ratio | 0% |
How did CUV perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield7%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 06:29 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clinuvel Pharmaceuticals Limited is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Wakim | Bell Potter |
| Norbert Kalliwoda | Dr. Kalliwoda Research |
| David Stanton | Jefferies LLC |